Heather Male, MD
Hematology & Oncology · Westwood, KSNPI 1437379914
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $650 of the $861 with a category attached, or 75.5%. Daiichi Sankyo Inc. accounts for 75.5% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $727, more than ten times the $14 reported in 2021. That places this record below the midpoint for hematology & oncology clinicians in KS, where the typical reported total is $1,410.
Across 5 payments — averaging $172.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$650
- Bristol Myers Squibb$120
- Sanofi-aventis U.S. LLC$42
- Gilead$35
- Acrotech Biopharma Inc.$14
Across 51 payments — averaging $13,188 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$532K
- Takeda Pharmaceuticals U.S.A., Inc.$139K
- National Marrow Donor Program$1K
What the payments were for
- Consulting fees$65076%
- Food & beverage$19723%
- Education$142%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 1 | $650 |
| Bristol Myers Squibb | 1 | $120 |
| Sanofi-aventis U.S. LLC | 1 | $42 |
| Gilead | 1 | $35 |
| Acrotech Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VANFLYTa$650
How this compares
$861 in reported general payments places this provider in the 35th percentile of 97 hematology & oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 13 | $15,097 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Westwood
- Priyanka SharmaWestwood$135K
- Gary DoolittleWestwood$102K
- Sunil AbhyankarWestwood$78K
- Leyla ShuneWestwood$56K
- Anthony SungWestwood$49K
- Anup Kumar Kasi Loknath KumarWestwood$31K
- Prakash NeupaneWestwood$26K
- Muhammad Umair MushtaqWestwood$21K
- Jesus Gonzalez LugoWestwood$4K
- Qamar KhanWestwood$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.